Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Benefits of Rehearsing Careful Nurturing - 2RSF attack on Sudan’s South Kordofan kills at least 14, including children
- 3Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- 4Dominating the Art of Composing: Creator Bits of knowledge
- 5Taste the World: Five Food sources That Have Dazzled Worldwide Palates
- Fundamental Archives for Beginning Your Business
- Instructions to Really Oversee Unsold SUVs in the Auto Business
- Israel reports killing another senior Iranian oil official
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Fundamental Venture The board Apparatuses for Remote Groups
- Intriguing Strange Cruising Objections you Should Visit
- Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- ByHeart infant formula recall tied to botulism outbreak puts parents on edge
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
